Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "TD"

1531 News Found

Ind-Swift Labs to pump Rs. 40 crore into Samba facility for global expansion
News | February 17, 2026

Ind-Swift Labs to pump Rs. 40 crore into Samba facility for global expansion

The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability


Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
News | February 14, 2026

Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods

Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore


Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY
News | February 14, 2026

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics
News | February 13, 2026

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore


Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
News | February 13, 2026

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25


Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million
News | February 11, 2026

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025


SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track
News | February 10, 2026

SMS Pharmaceuticals posts strong Q3 with 29% PAT growth, full-year targets on track

The company’s EBITDA margin remained resilient above 20%


Zydus Lifesciences reports strong Q3 & 9M FY26 growth
News | February 10, 2026

Zydus Lifesciences reports strong Q3 & 9M FY26 growth

Revenue from operations surged 30% year-on-year to Rs. 68,645 million